AJOVY is indicated for the preventive treatment of migraine in adults.

You can also browse the topics below to find what you are looking for.

SUSTAINED EFFICACY1 WITH NO EVIDENCE OF “WEARING OFF”2

Chronic Migraine

Patients experienced significantly more migraine-free days with AJOVY vs placebo in the HALO + Long-Term Extension Studies1,3-5

See Study Design >

Line chart describing clinical trial data of the pivotal HALO Chronic Migraine trial from months 1 to 3 and Long-Term Extension study from months 3 to 12.

Consider limitations of Long-Term Extension study design when interpreting efficacy results.

*Mean baseline of 12.8 headache days of at least moderate severity per month with monthly dosing.1

†Reduction in monthly average number of headache days from the Long-Term Extension study was 5.2 with quarterly dosing.3

PRIMARY ENDPOINT

Patients randomized to monthly dosing had a mean baseline of 12.8 headache days of at least moderate severity per month and experienced, on average1:

5.1 fewer headache days at month 3 vs 3.3 with placebo (P<0.001).3,4

Patients randomized to quarterly dosing had a mean baseline of 13.2 headache days of at least moderate severity per month and experienced, on average1:

4.7 fewer headache days at month 3 vs 3.3 with placebo (P<0.001).3,4

No evidence of “wearing off” with AJOVY was observed from one dose to the next2

POST HOC WEEKS 1-3 VS 4

Mean number of weekly migraine days during weeks 1-3 vs week 4 at months 3, 6, 9, and 15 with monthly dosing2‡

Bar chart showing Chronic Migraine post hoc analysis of mean number of weekly migraine days during weeks 1-3 vs week 4 at months 3, 6, 9, and 15 with monthly dosing.

POST HOC WEEKS 1-2 VS 11-12

Mean number of weekly migraine days in weeks 1-2 vs weeks 11-12 with quarterly dosing2‡

Bar chart showing Chronic Migraine post hoc analysis of mean number of weekly migraine days in weeks 1-2 vs week 11- 12 with quarterly dosing.

For all post hoc analyses, no determination of statistical significance can be made and no conclusions should be drawn.

‡Study design: Of the patients who rolled over from the HALO studies, 611 from the HALO CM study (monthly, n=305; quarterly, n=306) and 432 from the HALO EM study (monthly, n=215; quarterly, n=217) had received AJOVY injection during the respective HALO study and were included in post hoc analyses during the long-term, open-label extension study.2

NOW is the time for AJOVY

In clinical trials, AJOVY reduced migraine days by 50% or more for some patients1

SECONDARY ENDPOINT1

≥50% REDUCTION

in monthly number of migraine days with monthly dosing

40.8% vs 18.1% with placebo
(P<0.001)

EXPLORATORY ANALYSIS3

≥75% REDUCTION

in monthly number of migraine days with monthly dosing

20.6% vs 10.4% with placebo
(Exploratory analysis)

EXPLORATORY ANALYSIS3

100% REDUCTION

in monthly number of migraine days with monthly dosing

7.5% vs 4.2% with placebo
(Exploratory analysis)

For all exploratory analyses, no determination of statistical significance can be made and no conclusions should be drawn.

Similar reductions seen with quarterly dosing in chronic migraine patients§

§With quarterly dosing for chronic migraine patients, reduction in monthly average migraine days: 37.6% of patients achieved a ≥50% reduction vs 18.1% with placebo (P<0.001), 20% achieved a ≥75% reduction vs 10.4% with placebo (exploratory analysis), and 7.7% achieved 100% reduction vs 4.2% for placebo (exploratory analysis).1,3

​

References: 1. AJOVY® (fremanezumab-vfrm) injection Current Prescribing Information. North Wales, PA: Teva Pharmaceuticals USA, Inc. 2. Blumenfeld AM, Stevanovic DM, Ortega M, et al. Headache. 2020;60(10):2431-2443. 3. Data on file. Parsippany, NJ: Teva Pharmaceuticals USA, Inc. 4. Silberstein SD, Dodick DW, Bigal ME, et al. Fremanezumab for the preventive treatment of chronic migraine. N Engl J Med. 2017;377(22):2113-2122. 5. Goadsby PJ, Silberstein SD, Yeung PP, et al. Long-term safety, tolerability, and efficacy of fremanezumab in migraine: a randomized study. Neurology. 2020;95:e2487–e2499.